|
1
|
Chen L, Zhao M, Zhou M, Luo J, Li S, Liu X, Cheng Z, Zhuo Y, Zeng W, Zhang Z, Zhou L. LncRNA RP1-276N6.2 Expression and RP1-276N6.2 Gene Polymorphisms Contribute to the Risk of Coronary Artery Disease in Chinese Han Population. DNA Cell Biol 2023; 42:746-752. [PMID: 37843894 DOI: 10.1089/dna.2023.0202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2023] Open
Abstract
Long noncoding RNAs (lncRNAs) have been implicated in coronary artery disease (CAD) processes. However, the relationship between the gene polymorphisms of lncRNA RP1-276N6.2 as a novel molecule and susceptibility to CAD remains unclear. In our case-control study, 949 CAD patients and 892 healthy controls were genotyped using the TaqMan genotyping assay. The quantitative real-time polymerase chain reaction and enzyme-linked immunosorbent assay were performed to examine the expression levels of RP1-276N6.2 and SLC22A3(OCT3). We observed that CAD patients had significantly lower RP1-276N6.2 levels than those healthy participants (p < 0.05). Compared to the wild-type genotype, the rs611950 T allele and the rs10499313 AG genotype and G allele significantly increased the premature CAD risk (p = 0.02, p = 0.002, and p = 0.01, respectively), while the rs505000 G allele reduced this risk (p = 0.01); moreover, the rs505000 CG genotype significantly enhanced the delayed CAD risk (p = 0.03), and the rs505000 G allele reduced the expression levels of RP1-276N6.2 and SLC22A3 (p < 0.05 and p < 0.05, respectively). In addition, RP1-276N6.2 positively regulated the mRNA and secreted protein levels of SLC22A3 (p < 0.05). In conclusion, the RP1-276N6.2 gene polymorphisms were closely associated with CAD risk. LncRNA RP1-276N6.2 may be a potential genetic target for CAD early diagnosis and treatment.
Collapse
Affiliation(s)
- Lijuan Chen
- Department of Epidemiology, School of Public Health, Chongqing Medical University, Chongqing, China
| | - Mingming Zhao
- Department of Epidemiology, School of Public Health, Chongqing Medical University, Chongqing, China
| | - Mingsha Zhou
- Department of Epidemiology, School of Public Health, Chongqing Medical University, Chongqing, China
| | - Jia Luo
- Department of Epidemiology, School of Public Health, Chongqing Medical University, Chongqing, China
| | - Shan Li
- Department of Epidemiology, School of Public Health, Chongqing Medical University, Chongqing, China
| | - Xing Liu
- Department of Epidemiology, School of Public Health, Chongqing Medical University, Chongqing, China
| | - Zheng Cheng
- Department of Epidemiology, School of Public Health, Chongqing Medical University, Chongqing, China
| | - Yang Zhuo
- Department of Epidemiology, School of Public Health, Chongqing Medical University, Chongqing, China
| | - Weiqi Zeng
- Department of Epidemiology, School of Public Health, Chongqing Medical University, Chongqing, China
| | - Zhiyu Zhang
- Department of Epidemiology, School of Public Health, Chongqing Medical University, Chongqing, China
| | - Li Zhou
- Department of Epidemiology, School of Public Health, Chongqing Medical University, Chongqing, China
| |
Collapse
|
|
2
|
Rodríguez-Esparragón F, Torres-Mata LB, Cazorla-Rivero SE, Serna Gómez JA, González Martín JM, Cánovas-Molina Á, Medina-Suárez JA, González-Hernández AN, Estupiñán-Quintana L, Bartolomé-Durán MC, Rodríguez-Pérez JC, Varas BC. Analysis of ANRIL Isoforms and Key Genes in Patients with Severe Coronary Artery Disease. Int J Mol Sci 2023; 24:16127. [PMID: 38003316 PMCID: PMC10671206 DOI: 10.3390/ijms242216127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2023] [Revised: 10/24/2023] [Accepted: 11/07/2023] [Indexed: 11/26/2023] Open
Abstract
ANRIL (Antisense Noncoding RNA in the INK4 Locus), also named CDKN2B-AS1, is a long non-coding RNA with outstanding functions that regulates genes involved in atherosclerosis development. ANRIL genotypes and the expression of linear and circular isoforms have been associated with coronary artery disease (CAD). The CDKN2A and the CDKN2B genes at the CDKN2A/B locus encode the Cyclin-Dependent Kinase inhibitor protein (CDKI) p16INK4a and the p53 regulatory protein p14ARF, which are involved in cell cycle regulation, aging, senescence, and apoptosis. Abnormal ANRIL expression regulates vascular endothelial growth factor (VEGF) gene expression, and upregulated Vascular Endothelial Growth Factor (VEGF) promotes angiogenesis by activating the NF-κB signaling pathway. Here, we explored associations between determinations of the linear, circular, and linear-to-circular ANRIL gene expression ratio, CDKN2A, VEGF and its receptor kinase insert domain-containing receptor (KDR) and cardiovascular risk factors and all-cause mortality in high-risk coronary patients before they undergo coronary artery bypass grafting surgery (CABG). We found that the expression of ANRIL isoforms may help in the prediction of CAD outcomes. Linear isoforms were correlated with a worse cardiovascular risk profile while the expression of circular isoforms of ANRIL correlated with a decrease in oxidative stress. However, the determination of the linear versus circular ratio of ANRIL did not report additional information to that determined by the evaluation of individual isoforms. Although the expressions of the VEFG and KDR genes correlated with a decrease in oxidative stress, in binary logistic regression analysis it was observed that only the expression of linear isoforms of ANRIL and VEGF significantly contributed to the prediction of the number of surgical revascularizations.
Collapse
Affiliation(s)
- Francisco Rodríguez-Esparragón
- Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Gran Canaria, Spain; (L.B.T.-M.); (S.E.C.-R.); (J.A.S.G.); (J.M.G.M.); (Á.C.-M.); (J.A.M.-S.); (A.N.G.-H.); (L.E.-Q.); (M.C.B.-D.)
- Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Gran Canaria, Spain
- Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias de la Universidad de La Laguna, 38296 San Cristobal de La Laguna, Tenerife, Spain
- CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Laura B. Torres-Mata
- Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Gran Canaria, Spain; (L.B.T.-M.); (S.E.C.-R.); (J.A.S.G.); (J.M.G.M.); (Á.C.-M.); (J.A.M.-S.); (A.N.G.-H.); (L.E.-Q.); (M.C.B.-D.)
- Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Gran Canaria, Spain
- Department of Specific Didactics, University of Las Palmas de Gran Canaria, 35004 Las Palmas de Gran Canaria, Gran Canaria, Spain
| | - Sara E. Cazorla-Rivero
- Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Gran Canaria, Spain; (L.B.T.-M.); (S.E.C.-R.); (J.A.S.G.); (J.M.G.M.); (Á.C.-M.); (J.A.M.-S.); (A.N.G.-H.); (L.E.-Q.); (M.C.B.-D.)
- Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Gran Canaria, Spain
- Department of Internal Medicine, University of La Laguna, 38200 La Laguna, Tenerife, Spain
| | - Jaime A. Serna Gómez
- Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Gran Canaria, Spain; (L.B.T.-M.); (S.E.C.-R.); (J.A.S.G.); (J.M.G.M.); (Á.C.-M.); (J.A.M.-S.); (A.N.G.-H.); (L.E.-Q.); (M.C.B.-D.)
- Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Gran Canaria, Spain
- Deparment of Cardiovascular Surgery, Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Gran Canaria, Spain
| | - Jesús M. González Martín
- Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Gran Canaria, Spain; (L.B.T.-M.); (S.E.C.-R.); (J.A.S.G.); (J.M.G.M.); (Á.C.-M.); (J.A.M.-S.); (A.N.G.-H.); (L.E.-Q.); (M.C.B.-D.)
- Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Gran Canaria, Spain
- CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, 28029 Madrid, Spain
| | - Ángeles Cánovas-Molina
- Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Gran Canaria, Spain; (L.B.T.-M.); (S.E.C.-R.); (J.A.S.G.); (J.M.G.M.); (Á.C.-M.); (J.A.M.-S.); (A.N.G.-H.); (L.E.-Q.); (M.C.B.-D.)
- Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Gran Canaria, Spain
- Chronic Pain Unit, Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Gran Canaria, Spain
| | - José A. Medina-Suárez
- Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Gran Canaria, Spain; (L.B.T.-M.); (S.E.C.-R.); (J.A.S.G.); (J.M.G.M.); (Á.C.-M.); (J.A.M.-S.); (A.N.G.-H.); (L.E.-Q.); (M.C.B.-D.)
- Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Gran Canaria, Spain
- Department of Specific Didactics, University of Las Palmas de Gran Canaria, 35004 Las Palmas de Gran Canaria, Gran Canaria, Spain
| | - Ayose N. González-Hernández
- Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Gran Canaria, Spain; (L.B.T.-M.); (S.E.C.-R.); (J.A.S.G.); (J.M.G.M.); (Á.C.-M.); (J.A.M.-S.); (A.N.G.-H.); (L.E.-Q.); (M.C.B.-D.)
- Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Gran Canaria, Spain
- Deparment of Neurology and Clinical Neurophysiology, Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Gran Canaria, Spain
| | - Lidia Estupiñán-Quintana
- Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Gran Canaria, Spain; (L.B.T.-M.); (S.E.C.-R.); (J.A.S.G.); (J.M.G.M.); (Á.C.-M.); (J.A.M.-S.); (A.N.G.-H.); (L.E.-Q.); (M.C.B.-D.)
- Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Gran Canaria, Spain
| | - María C. Bartolomé-Durán
- Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Gran Canaria, Spain; (L.B.T.-M.); (S.E.C.-R.); (J.A.S.G.); (J.M.G.M.); (Á.C.-M.); (J.A.M.-S.); (A.N.G.-H.); (L.E.-Q.); (M.C.B.-D.)
- Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Gran Canaria, Spain
| | - José C. Rodríguez-Pérez
- Vice Chancellor of Research, Universidad Fernando Pessoa Canarias, 35002 Santa María de Guía de Gran Canaria, Gran Canaria, Spain;
| | - Bernardino Clavo Varas
- Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Gran Canaria, Spain; (L.B.T.-M.); (S.E.C.-R.); (J.A.S.G.); (J.M.G.M.); (Á.C.-M.); (J.A.M.-S.); (A.N.G.-H.); (L.E.-Q.); (M.C.B.-D.)
- Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Gran Canaria, Spain
- Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias de la Universidad de La Laguna, 38296 San Cristobal de La Laguna, Tenerife, Spain
- CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, 28029 Madrid, Spain
- Chronic Pain Unit, Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Gran Canaria, Spain
- Radiation Oncology Department, Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Gran Canaria, Spain
- Universitary Institute for Research in Biomedicine and Health (iUIBS), Molecular and Translational Pharmacology Group, University of Las Palmas de Gran Canaria, 35016 Las Palmas de Gran Canaria, Gran Canaria, Spain
- Spanish Group of Clinical Research in Radiation Oncology (GICOR), 28290 Madrid, Spain
| |
Collapse
|
|
3
|
López Rodríguez M, Arasu UT, Kaikkonen MU. Exploring the genetic basis of coronary artery disease using functional genomics. Atherosclerosis 2023; 374:87-98. [PMID: 36801133 DOI: 10.1016/j.atherosclerosis.2023.01.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/31/2022] [Revised: 01/20/2023] [Accepted: 01/24/2023] [Indexed: 02/05/2023]
Abstract
Genome-wide Association Studies (GWAS) have identified more than 300 loci associated with coronary artery disease (CAD), defining the genetic risk map of the disease. However, the translation of the association signals into biological-pathophysiological mechanisms constitute a major challenge. Through a group of examples of studies focused on CAD, we discuss the rationale, basic principles and outcomes of the main methodologies implemented to prioritize and characterize causal variants and their target genes. Additionally, we highlight the strategies as well as the current methods that integrate association and functional genomics data to dissect the cellular specificity underlying the complexity of disease mechanisms. Despite the limitations of existing approaches, the increasing knowledge generated through functional studies helps interpret GWAS maps and opens novel avenues for the clinical usability of association data.
Collapse
Affiliation(s)
- Maykel López Rodríguez
- A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, 70211, Finland; Department of Pathology and Laboratory Medicine, University of California, UCLA, Los Angeles, USA.
| | - Uma Thanigai Arasu
- A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, 70211, Finland
| | - Minna U Kaikkonen
- A. I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, 70211, Finland.
| |
Collapse
|
|
5
|
Petković A, Erceg S, Munjas J, Ninić A, Sopić M. Circulating non-coding RNAs as biomarkers in coronary artery disease. ARHIV ZA FARMACIJU 2022. [DOI: 10.5937/arhfarm72-36166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022] Open
Abstract
Coronary artery disease (CAD) is a leading cause of mortality worldwide. Atherosclerosis involves an interplay of different pathological mechanisms, such as progressive inflammation, abnormal lipid metabolism, and oxidative stress, and as such represents the basic pathological phenomenon underlying CAD. Atherosclerotic plaque narrows the lumen of coronary arteries, creating an ischemic environment for the heart muscle, which finally leads to clinical complications, such as acute myocardial infarction. Currently, there are no biomarkers that could predict plaque stability or major adverse cardiovascular events (MACE). Numerous functional non-coding RNA (ncRNA) species influence basic cellular functions, and as such play a role in the development and progression of CAD. Of these ncRNAs, micro RNAs (miRNAs) and long non-coding RNAs (lncRNAs) are the most investigated. Considering that ncRNAs detected in extracellular fluids can originate from different cells, circulating ncRNAs are being intensively investigated as potential biomarkers in the diagnosis and prognosis of CAD. In the following paper, we provide current insights into potential molecular mechanisms by which miRNAs and lncRNAs contribute to the pathology of CAD and discuss their potential role as biomarkers in diagnosis and prognosis of disease.
Collapse
|